Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Highlighting Success: Asian Minority Representation in the Hematology-Oncology Workforce

Lewis T Go, Lucas T Go, Madugodaralalaage DSK Gunaratne, Aneel A Ashrani, Michelle A Elliott, Richard C Godby, C Christopher Hook, Leslie J Padrnos, Rajiv K Pruthi, Candido E Rivera, Rachelle L Rouse, Surbhi Shah, Marwan E Shaikh, Mustaqeem A Siddiqui, Meera Sridharan, Ewa M Wysokinska, Alexandra P Wolanskyj-Spinner, Ronald S Go, Jithma P Abeykoon

Blood (2024) 144 (Supplement 1): 7946.

https://doi.org/10.1182/blood-2024-199887

Published: 2024

Journal Articles

Assessment of Classical Hematologists and Hematology-Focused Fellowship Programs at NCI-Designated Cancer Centers: Implications for Addressing Workforce Shortages and Enhancing Mentorship Opportunities

Lewis T Go, Lucas T Go, Madugodaralalaage DSK Gunaratne, Aneel A Ashrani, Michelle A Elliott, Richard C Godby, C Christopher Hook, Leslie J Padrnos, Rajiv K Pruthi, Candido E Rivera, Rachelle L Rouse, Surbhi Shah, Marwan E Shaikh, Mustaqeem A. Siddiqui, Meera Sridharan, Ewa M Wysokinska, Alexandra P Wolanskyj-Spinner, Ronald S Go, Jithma P Abeykoon

Blood (2024) 144 (Supplement 1): 613.

https://doi.org/10.1182/blood-2024-194745

Published: 2024

Journal Articles

Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-138657

Published: 2020

Journal Articles

Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies

Miguel Gonzalez Velez, MD, Carolyn Mead-Harvey, MS, Heidi E. Kosiorek, MS, Yael Kusne, MD PhD, Leyla Bojanini, MD, Candido E. Rivera, MD, Donald Northfelt, MD, Chung-II Wi, MD, Leslie Padrnos, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-142897

Published: 2020

Journal Articles

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Zaid Abdel Rahman, MD, Nicole Gannon, PA-C, Megan Melody, MD, Paul Muniz, RN, Ernesto Ayala, MD, Vivek Roy, MD, Lisa Brumble, Sikander Ailawadhi, MD, Taimur Sher, MD, James M. Foran, MD, Hemant S. Murthy, MD, Han W. Tun, MD, Candido E. Rivera, MD, Asher A. Chanan-Khan, MD, Abba C. Zubair, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA

Blood (2019) 134 (Supplement_1): 5610.

https://doi.org/10.1182/blood-2019-122067

Published: 2019

Journal Articles

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Stephen T Oh, MD PhD, Moshe Talpaz, MD, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD FACP, Carole Brennan Miller, MD, Candido E. Rivera, MD, Angela Fleischman, MD PhD, Swati Goel, Mark L Heaney, MD PhD, Casey O'Connell, MD, Murat Arcasoy, MD, Yafeng Zhang, PhD MD, Jun Kawashima, MD, Tomas Ganz, MD PhD, Carrie Baker Brachmann

Blood (2018) 132 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2018-99-111349

Published: 2018

Journal Articles

Identification of a Novel Heterozygous Mutation ( c.2213T>G;p.Leu738Arg ) in Platelet Glycoprotein ITGB3 gene in a Patient with Glanzmann's Thrombasthenia

Candido E. Rivera, MD, Prakash Vishnu, MD, Gretchen Schaef Johns, MD, Rajiv K. Pruthi, M.B.B.S., Dong Chen, MD PhD

Blood (2018) 132 (Supplement 1): 1158.

https://doi.org/10.1182/blood-2018-99-117995

Published: 2018

Journal Articles

Clinical Outcomes and Cost Analysis of Dose-Adjusted R-EPOCH Vs R-CHOP in Treatment of Diffuse Large B- Cell Lymphoma with High Risk Features

Bhagirathbhai Dholaria, MBBS, Prakash Vishnu, MD, Yenni Alejandro Moreno-Vanegas, Aaron C. Spaulding, Nancy N. Diehl, David Hodge, Candido E. Rivera, MD, Han Tun, MD

Blood (2018) 132 (Supplement 1): 4790.

https://doi.org/10.1182/blood-2018-99-117743

Published: 2018

Journal Articles

DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B- Cell Lymphoma: The Mayo Clinic Florida Experience

Bhagirathbhai Dholaria, MBBS, Prakash Vishnu, MD FACP, Vivek Roy, MD, Han W Tun, MD, Taimur Sher, MD, Candido E. Rivera, MD, Sikander Ailawadhi, Nancy Diehl, David O. Hodge, MS, Yenni Alejandro Moreno-Vanegas

Blood (2017) 130 (Supplement 1): 1572.

https://doi.org/10.1182/blood.V130.Suppl_1.1572.1572

Published: 2017

Journal Articles

Splenectomy or Rituximab in Steroid-Refractory Immune Thrombocytopenia (ITP): The Mayo Clinic Experience

William A. Hammond, MD, Elisa M. Rodriguez, Zhuo Li, M.S, Bhagirathbhai Dholaria, MBBS, Amanda Shreders, MD, Prakash Vishnu, MD, Candido E. Rivera, MD

Blood (2016) 128 (22): 3735.

https://doi.org/10.1182/blood.V128.22.3735.3735

Published: 2016

Journal Articles

Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)

Srdan Verstovsek, MD PhD, Moshe Talpaz, MD, Ellen K. Ritchie, MD, Martha Wadleigh, MD, Olatoyosi Odenike, MD, Catriona Jamieson, MD PhD, Brady Stein, MD, Candido E. Rivera, MD, Tomonori Uno, PhD, Ruben A. Mesa, MD

Blood (2016) 128 (22): 1936.

https://doi.org/10.1182/blood.V128.22.1936.1936

Published: 2016

Journal Articles

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study

Ayed O. Ayed, MD, Levi Pederson, William R. Macon, MD, Betsy R. Laplant, MS, Craig B. Reeder, MD, James M. Foran, MD, Garth Nelson, Candido E. Rivera, MD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD

Blood (2016) 128 (22): 5322.

https://doi.org/10.1182/blood.V128.22.5322.5322

Published: 2016

Journal Articles

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Blood (2016) 128 (20): 2415–2422.

https://doi.org/10.1182/blood-2016-05-717769

Published: 2016

Journal Articles

Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotininb: Correlatives from the Ym-387-II Study

Vikas Gupta, MD FRCP, FRCPath, Ruben A. Mesa, Michael W Deininger, MD PhD, Candido E. Rivera, MD, Shireen Sirhan, MD FRCP, Srdan Verstovsek, MD, Yafeng Zhang, PhD, Yuanyuan Xiao, PhD, Helen Collins, MD, Kevin Kwei, Adarsh Joshi, PhD, Carrie Baker Brachmann, PhD

Blood (2015) 126 (23): 1600.

https://doi.org/10.1182/blood.V126.23.1600.1600

Published: 2015

Journal Articles

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Aneel Paulus, MDMS, Pooja Advani, MBBS, Betsy R. Laplant, MS, Sharoon Akhtar, MPhil, Taimur Sher, MD, Candido E. Rivera, MD, James M. Foran, MD, Vivek Roy, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 5299.

https://doi.org/10.1182/blood.V126.23.5299.5299

Published: 2015

Journal Articles

Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199

Sharoon Akhtar, MPhil, Aneel Paulus, MDMS, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Vivek Roy, MD, Taimur Sher, MD, James M. Foran, MD, Candido E. Rivera, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 4839.

https://doi.org/10.1182/blood.V126.23.4839.4839

Published: 2015

Journal Articles

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

Aneel Paulus, MDMS, Kasyapa S. Chitta, PhD, Sharoon Akhtar, MPhil, Hassan Yousaf, Davitte Cogen, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Taher Abbasi, James M. Foran, MD, Candido E. Rivera, MD, Taimur Sher, MD, Vivek Roy, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 2754.

https://doi.org/10.1182/blood.V126.23.2754.2754

Published: 2015

Journal Articles

Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood (2015) 126 (23): 3050.

https://doi.org/10.1182/blood.V126.23.3050.3050

Published: 2015

Journal Articles

Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib

Shaji K Kumar, MD, Vivek Roy, M.D., Craig Reeder, MD, Betsy R. LaPlant, Martha Q Lacy, MD, Morie A Gertz, MD, MACP, Kristina Laumann, Melanie Ann Thompson, Thomas E Witzig, MD, Francis K Buadi, MD, Candido E. Rivera, MD, Joseph R. Mikhael, MD, Peter Leif Bergsagel, MD, Lisa Hwa, RN, CNP, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD

Blood (2013) 122 (21): 1944.

https://doi.org/10.1182/blood.V122.21.1944.1944

Published: 2013

Journal Articles

Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs

Aneel Paulus, MD, MS, Kasyapa S. Chitta, PhD, Sharoon Akhtar, Maja Kuranz, Shaji Kumar, MD, Vivek Roy, MD, FACP, Stephen M. Ansell, M.D.Ph.D., Joseph R. Mikhael, MD, Angela Dispenzieri, MD, Craig Reeder, MD, Candido E. Rivera, MD, James M. Foran, MD, Francis Buadi, MD, Vincent Rajkumar, MD, Asher Chanan-Khan, MD

Blood (2013) 122 (21): 1928.

https://doi.org/10.1182/blood.V122.21.1928.1928

Published: 2013

NARROW

Highlighting Success: Asian Minority Representation in the Hematology-Oncology Workforce

Assessment of Classical Hematologists and Hematology-Focused Fellowship Programs at NCI-Designated Cancer Centers: Implications for Addressing Workforce Shortages and Enhancing Mentorship Opportunities

Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors

Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Identification of a Novel Heterozygous Mutation ( c.2213T>G;p.Leu738Arg ) in Platelet Glycoprotein ITGB3 gene in a Patient with Glanzmann's Thrombasthenia

Clinical Outcomes and Cost Analysis of Dose-Adjusted R-EPOCH Vs R-CHOP in Treatment of Diffuse Large B- Cell Lymphoma with High Risk Features

DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B- Cell Lymphoma: The Mayo Clinic Florida Experience

Splenectomy or Rituximab in Steroid-Refractory Immune Thrombocytopenia (ITP): The Mayo Clinic Experience

Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotininb: Correlatives from the Ym-387-II Study

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib

Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only